A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients with Progressive, Advanced, Kinase Inhibitor Naive, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531).

  • Topliss, Duncan (Primary Chief Investigator (PCI))
  • Davids, Faeeza (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date11/08/20 → 3/03/23

Keywords

  • Endocrinology
  • Thyroid cancer
  • Clinical trial